Literature DB >> 15249627

L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.

H Russmann1, J Ghika, P Combrement, J G Villemure, J Bogousslavsky, P R Burkhard, F J G Vingerhoets.   

Abstract

The authors studied the long-term evolution of levodopa-induced dyskinesia (LID) after levodopa challenge in two groups of six STN-deep brain stimulation-treated Parkinson disease (PD) patients, one requiring medication after surgery and the other not. A dramatic (96%) reduction of LID severity was obtained in the six postoperatively untreated patients compared to a moderate improvement (47%) in the treated group (p < 0.03). These data support dopaminergic stimulation and striatal desensitization as major determinants of LID in PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249627     DOI: 10.1212/01.wnl.0000131910.72829.9d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Deep brain stimulation.

Authors:  Joel S Perlmutter; Jonathan W Mink
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

2.  Deep brain stimulation effect on anterior pallidum reduces motor impulsivity in Parkinson's disease.

Authors:  Khaled Moussawi; Min Jae Kim; Sydney Baybayan; Myles Wood; Kelly A Mills
Journal:  Brain Stimul       Date:  2021-11-05       Impact factor: 8.955

3.  Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.

Authors:  Shi-Ying Fan; Kai-Liang Wang; Wei Hu; Robert S Eisinger; Alexander Han; Chun-Lei Han; Qiao Wang; Shimabukuro Michitomo; Jian-Guo Zhang; Feng Wang; Adolfo Ramirez-Zamora; Fan-Gang Meng
Journal:  Ann Clin Transl Neurol       Date:  2019-12-08       Impact factor: 4.511

4.  Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease.

Authors:  Jiping Li; Shanshan Mei; Xiaofei Jia; Yuqing Zhang
Journal:  Front Neurol       Date:  2021-04-12       Impact factor: 4.003

5.  The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation.

Authors:  Ondrej Bezdicek; Josef Mana; Filip Růžička; Filip Havlik; Anna Fečíková; Tereza Uhrová; Evžen Růžička; Dušan Urgošík; Robert Jech
Journal:  Front Aging Neurosci       Date:  2022-06-17       Impact factor: 5.702

6.  The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.

Authors:  Asier Aristieta; Garikoitz Azkona; Ainhoa Sagarduy; Cristina Miguelez; José Ángel Ruiz-Ortega; Rosario Sanchez-Pernaute; Luisa Ugedo
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

7.  Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications.

Authors:  Jan Vesper; Susanne Haak; Christoph Ostertag; Guido Nikkhah
Journal:  BMC Neurol       Date:  2007-03-16       Impact factor: 2.474

8.  Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.

Authors:  Ji Hee Kim; Won Seok Chang; Hyun Ho Jung; Jin Woo Chang
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

Review 9.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

10.  Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Xiao Dong Liu; Yi Bao; Guang Jian Liu
Journal:  Front Neurol       Date:  2019-08-27       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.